DrugPatentWatch Database Preview
Drugs in Development Information for Oprelvekin
» See Plans and Pricing
What is the development status for investigational drug Oprelvekin?
Oprelvekin is an investigational drug.
There have been 4 clinical trials for Oprelvekin.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2008.
The most common disease conditions in clinical trials are Von Willebrand Diseases, Thrombocytopenia, and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. The leading clinical trial sponsors are Wyeth is now a wholly owned subsidiary of Pfizer, University of Pittsburgh, and University of North Carolina.
Summary for Oprelvekin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2008-02-01) |
| Vendors | 0 |
Recent Clinical Trials for Oprelvekin
| Title | Sponsor | Phase |
|---|---|---|
| Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia | Pfizer | Phase 2 |
| IL-11 in Adults With Von Willebrand Disease Undergoing Surgery | University of North Carolina | Phase 2 |
| IL-11 in Adults With Von Willebrand Disease Undergoing Surgery | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 2 |
Clinical Trial Summary for Oprelvekin
Top disease conditions for Oprelvekin
Top clinical trial sponsors for Oprelvekin
US Patents for Oprelvekin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
